Verified loading…
FDA · EMA · ClinicalTrials.gov · Published literature
DECISION SUPPORTREVIEWED

Hematology — What to know, what to ask, what to do

A structured, at-a-glance aid — not medical advice. Use it to have a sharper conversation with your specialist and to get trial- and therapy-ready.

Aligned with ASH, WFH, NHF/MASAC · Reviewed 2026-07-11

PREVALENCE · Hemophilia affects roughly 1 in 5,000 male births (Hemophilia A) and 1 in 25,000 (Hemophilia B); von Willebrand disease is the most common inherited bleeding disorder, affecting up to ~1% of the population. Rare factor deficiencies and platelet-function disorders add hundreds of thousands more.HORIZON · Hemophilia B: functional cure available now (Hemgenix). Hemophilia A: gene therapy approved, durability under study. Von Willebrand disease: pivotal rebalancing trials, 2–4 years. Rare factors & platelet disorders: 5–10+ years.

Hematology has crossed the line from lifelong management to functional cure for its flagship disease. Two one-time gene therapies are now approved — Hemgenix for Hemophilia B (2022) and Roctavian for Hemophilia A (2023) — delivering a working clotting-factor gene to the liver so patients make their own factor for years. A parallel “rebalancing” class (fitusiran, concizumab) lowers natural anticoagulants instead of replacing factor, working across inhibitor status and by subcutaneous injection. Von Willebrand disease, long the neglected majority, finally has a mechanism-specific therapy (anti–Protein S) in pivotal trials. The remaining frontiers are durability, the rare factor deficiencies, and platelet-function disorders.

MAJOR FORMS

Hemophilia B (Factor IX deficiency)

The furthest along toward cure: Hemgenix gene therapy uses the hyperactive Padua Factor IX variant for durable, near-normal expression — the clearest existence proof of a functional cure in a bleeding disorder.

Hemophilia A (Factor VIII deficiency)

Gene therapy (Roctavian) is approved and emicizumab set a high prophylaxis bar, but Factor VIII expression declines year over year — durability is the defining open question.

Von Willebrand disease

The most common inherited bleeding disorder and historically the most neglected; anti–Protein S therapy (VGA039) is the first mechanism-specific approach, now in pivotal trials.

Rare factor deficiencies (V, VII, X, XI, XIII)

A heterogeneous group ranging from plasma-only parahemophilia (Factor V) to approved concentrates (Factor X/Coagadex, Factor XIII/Tretten) and emerging AAV and antibody approaches (Factor XI abelacimab/milvexian).

Platelet-function disorders

Glanzmann thrombasthenia and Bernard-Soulier syndrome are the frontier — lentiviral and gene-editing approaches are in early (Phase 1) study, the least mature corner of the field.

THERAPY LANDSCAPE

REAL-WORLDHemgenix (etranacogene dezaparvovec) — Hemophilia B gene therapy
FOR WHOMAdults with moderately severe to severe Hemophilia B (Factor IX deficiency) without pre-existing high-titer AAV5 neutralizing antibodies. Uses the hyperactive Padua variant for supraphysiologic expression from a single infusion.
EVIDENCEHOPE-B pivotal data show mean Factor IX activity in the mild-to-near-normal range with ~64% reduction in annualized bleed rate and the large majority off prophylaxis; durability now tracked past 3–4 years.
ACCESSFDA-approved (2022). Delivered at specialized hemophilia treatment centers after AAV5 antibody screening. List price ~$3.5M — the context is a lifetime factor cost often exceeding $20M.

CAUTION · Pre-existing high-titer neutralizing antibodies to the AAV5 capsid; Active or significant underlying liver disease (affects hepatocyte expression and safety)

Annualized bleed reduction: ~64%Off routine prophylaxis: Large majorityDosing: One-time infusion
APPROVEDRoctavian (valoctocogene roxaparvovec) — Hemophilia A gene therapy
FOR WHOMAdults with severe Hemophilia A (Factor VIII deficiency) without anti-AAV5 antibodies or active inhibitors. A single AAV5 infusion delivers a B-domain-deleted Factor VIII transgene to hepatocytes.
EVIDENCEGENEr8-1 showed a marked drop in annualized bleed rate and near-elimination of factor use in year one, but Factor VIII expression declines measurably year over year — making durability the central open question rather than initial efficacy.
ACCESSFDA-approved (2023). Specialized centers only, after antibody screening. List price ~$2.9M.

CAUTION · Pre-existing anti-AAV5 neutralizing antibodies; Active Factor VIII inhibitors; Significant liver disease

Year-1 bleed reduction: SubstantialDurability: Declines year over yearDosing: One-time infusion
REAL-WORLDEmicizumab (Hemlibra) — factor-mimetic prophylaxis
FOR WHOMHemophilia A with or without Factor VIII inhibitors. A bispecific antibody that bridges activated Factor IX and Factor X, mimicking Factor VIII cofactor function — subcutaneous, as infrequently as every 1–4 weeks.
EVIDENCEHAVEN program demonstrated ~68–87% reductions in treated bleeds versus prior regimens and transformed prophylaxis for inhibitor patients — the current standard-of-care benchmark any cure must beat.
ACCESSFDA-approved and widely used; the real-world prophylaxis benchmark.
Bleed reduction: ~68–87%Dosing: Subcutaneous, q1–4 weeks
APPROVEDRebalancing therapies (fitusiran, concizumab/Alhemo)
FOR WHOMHemophilia A or B, with or without inhibitors. Fitusiran is a siRNA lowering antithrombin; concizumab is an anti–TFPI antibody — both restore thrombin generation by removing brakes rather than adding clotting factor, and both are subcutaneous.
EVIDENCEBoth classes achieved significant annualized-bleed reductions across inhibitor and non-inhibitor populations; concizumab (Alhemo) and fitusiran (Qfitlia) have reached regulatory approval, expanding low-burden options beyond Factor VIII/IX pathways.
ACCESSApproved; requires monitoring of thrombotic risk given the rebalanced hemostatic state.

CAUTION · History of thrombosis or high thrombotic risk (rebalancing narrows the safety margin)

Mechanism: Antithrombin / TFPI loweringDosing: Subcutaneous
PHASE 3VGA039 — anti–Protein S therapy for von Willebrand disease
FOR WHOMVon Willebrand disease across subtypes — a monoclonal antibody targeting Protein S to enhance thrombin generation, addressing the long-unmet need for a mechanism-specific VWD therapy rather than on-demand factor concentrate.
EVIDENCEEarly VIVID-program data report a 73–100% reduction in bleeding across evaluated participants — a striking signal now moving into pivotal evaluation.
ACCESSInvestigational — pivotal (VIVID-6) trials. Not yet approved.
Early bleed reduction: 73–100%Stage: Phase 3 (VIVID-6)

WHEN TO ACT

  • Gene therapy vs. modern prophylaxis is the central fork: emicizumab and rebalancing agents set a high, low-burden bar, so gene therapy is chosen for the prospect of years off treatment — weighed against durability uncertainty (especially in Hemophilia A) and one-shot AAV immunity.
  • Inhibitor status reshapes options: with inhibitors, factor-mimetic (emicizumab) and rebalancing therapies work independently of the inhibitor, while inhibitor eradication (immune tolerance induction) remains a parallel decision.
  • For von Willebrand disease, the fork is on-demand/DDAVP-guided management versus enrolling in a mechanism-specific trial (anti–Protein S) — a decision that hinges on subtype, bleeding phenotype and DDAVP responsiveness.

RED FLAGS — SEEK CARE

  • Spontaneous joint bleeding (warmth, swelling, limited motion) — especially recurrent in the same joint
  • Any head injury with headache, vomiting, drowsiness or confusion (possible intracranial bleed — emergency)
  • Prolonged or uncontrollable bleeding after minor cuts, dental work or surgery
  • Blood in urine or stool, or unusually heavy or prolonged menstrual bleeding
  • A new poor response to a factor product that previously worked (possible inhibitor development)

QUESTIONS FOR YOUR SPECIALIST

  • What is my exact diagnosis, subtype and baseline factor level?
  • Am I a candidate for gene therapy — and what is my AAV5 antibody status?
  • How does my current bleed rate compare with what gene or rebalancing therapy could offer?
  • What are the durability data for my specific therapy, and what happens if it wanes?
  • Do I have or am I at risk of inhibitors, and how would that change my options?
  • Are there trials I qualify for, and do any involve a treatment-free washout period?
  • What are my thrombotic risks if I use a rebalancing therapy?
  • Which Hemophilia Treatment Center should manage my advanced therapy?

GET TRIAL-READY

  • Confirm the precise diagnosis and subtype — specific factor assay (VIII, IX, XI, etc.), von Willebrand panel (VWF:Ag, VWF activity, Factor VIII), and genotype where available. Gene and rebalancing therapies are subtype-specific; a vague label is not enough to act on.
  • Screen AAV5 neutralizing-antibody status early if gene therapy is being considered — it is the single gatekeeper for eligibility and determines whether the entire pathway is open.
  • Document a quantitative bleeding history and current treatment burden — annualized bleed rate, infusion/injection frequency, joint health, and prior inhibitor history — the baseline any therapy decision is measured against.
  • Establish care at a Hemophilia Treatment Center (HTC) — gene and rebalancing therapies are delivered and monitored there, and HTC care independently improves outcomes.
  • Assemble a proof binder and safety labs — baseline liver assessment (for AAV therapies), inhibitor testing, and for VWD candidates a Protein S level — so eligibility can be confirmed without delay when a slot opens.
  • For trial candidates, verify washout and crossover design before enrolling — single-sequence crossover trials can require a treatment-free window that is dangerous in a severe bleeding phenotype; understand it in advance.

REALITY CHECK

  • ·Gene therapy is a functional cure, not a permanent one — yet. Hemophilia B (Hemgenix) shows durable, near-normal Factor IX years out, but Hemophilia A (Roctavian) Factor VIII expression declines measurably year over year, and no one can yet promise lifetime coverage. Re-dosing is blocked by anti-AAV5 immunity, so the first shot has to count.
  • ·AAV immunity excludes a large minority. Pre-existing neutralizing antibodies to the AAV5 capsid — present in a substantial share of adults — disqualify patients from current gene therapies entirely. Next-generation capsids and immune-modulation strategies aim to widen eligibility but are not yet standard.
  • ·Rebalancing therapies trade one risk for another. Lowering antithrombin or TFPI restores clotting without factor, but narrows the margin against thrombosis — dosing and monitoring were refined precisely because of thrombotic safety signals. They are powerful, not free.
  • ·Von Willebrand disease and rare factors remain under-served. VWD affects up to 1% of people yet had no mechanism-specific therapy until recently; parahemophilia (Factor V) still relies on plasma, and platelet-function disorders have only early cell/gene approaches. The cure story is real but uneven across the family of bleeding disorders.

DECISION-DRIVING TESTS & BIOMARKERS

Factor VIII / Factor IX activity levelAnti-AAV5 neutralizing antibodiesFactor inhibitor titer (Bethesda units)Von Willebrand panel (VWF:Ag, VWF activity, Factor VIII)Protein S level (VWD therapy safety)

EVERY PATH TO ENDING BLEEDING DISORDERS

Six families define the landscape: liver-directed gene therapy (furthest along), factor-mimetic and rebalancing biologics, the emerging von Willebrand mechanism-specific class, the heterogeneous rare-factor concentrates and pipelines, and the earliest-stage platelet-disorder gene approaches. Maturity ranges from functional cure to preclinical.

From Lifelong Infusions to One-Time Cures

Hematology delivered one of medicine’s first true functional cures: a single infusion that makes a person with Hemophilia B produce their own clotting factor for years. The template — a validated target, a durable delivery platform, and a hard efficacy endpoint (annualized bleed rate) — now propagates outward: to Hemophilia A (where durability is the work), to rebalancing biologics that sidestep the deficient factor entirely, to von Willebrand disease’s first mechanism-specific therapy, and to the rare-factor and platelet frontiers. The through-line is that “lifelong management” is being replaced, disorder by disorder, with something closer to a fix.

THE COAGULATION CASCADE — AND WHERE EACH THERAPY ACTS

Modern hemostasis is understood as a cell-based, three-phase process rather than the classic waterfall. Mapping each phase clarifies exactly where a deficiency causes bleeding and where each therapy intervenes — replacement, mimetic, rebalancing or gene-level.

1Initiation

Tissue factor exposure triggers a small burst of thrombin

Vessel injury exposes tissue factor, which complexes with Factor VIIa to activate Factor X and Factor IX, generating an initial small amount of thrombin on tissue-factor-bearing cells.

AI ANGLE · Factor VII/X deficiencies and the anti-TFPI rebalancing strategy both act here — modulating the initiation threshold.

Tissue factorFactor VIIaFactor IXFactor X
2Amplification

Thrombin primes the system on the platelet surface

The initial thrombin activates platelets and the cofactors Factor V, Factor VIII and Factor XI on the platelet surface — arming the machinery for a large-scale response.

AI ANGLE · Hemophilia A (Factor VIII) and Factor XI deficiency manifest here; emicizumab substitutes for Factor VIII cofactor function at this step.

ThrombinFactor VIIIFactor VFactor XIPlatelets
3Propagation

A thrombin burst builds and stabilizes the fibrin clot

The tenase and prothrombinase complexes drive a large thrombin burst that converts fibrinogen to fibrin; Factor XIIIa then cross-links fibrin into a stable clot.

AI ANGLE · Hemophilia B (Factor IX) limits the tenase-driven burst; gene therapy restores endogenous Factor IX/VIII so propagation proceeds normally, while Factor XIII deficiency destabilizes the finished clot.

Tenase complexFibrinFactor XIIIaClot stabilization

THE ROCTAVIAN REALITY CHECK

What the first approved Hemophilia A gene therapy actually delivers — and the durability debate that defines its future.

GENEr8-1 showed a marked reduction in annualized bleed rate and near-elimination of factor use in year one — a genuine milestone as the first approved Hemophilia A gene therapy.

A single AAV5 infusion delivers a Factor VIII gene to liver cells.

Year-one results: large drop in bleeds and most patients off routine factor.

Approved by the FDA in 2023 after conditional European approval.

It proved a large, hard-to-express factor could be delivered by gene therapy at all.

WHAT A CURE ACTUALLY LOOKS LIKE

Hemophilia B is the proof that a functional cure is real — what it means biologically, practically and economically.

Hemgenix produces durable, near-normal Factor IX activity years after one infusion, with the large majority off prophylaxis — a functional cure by any practical definition.

The Padua Factor IX variant produces high activity per gene copy.

Most treated patients came off routine factor entirely.

Benefit has been tracked past three to four years.

This is the clearest existence proof of a cure in a bleeding disorder.

THE WASHOUT PROBLEM

Why some pivotal bleeding-disorder trials require a dangerous treatment-free window — and how modern trial design is fixing it.

Single-sequence crossover designs (as in some VWD programs) can require a treatment-free washout to establish baseline — a genuine danger in a severe bleeding phenotype.

A washout period means stopping effective treatment temporarily.

In severe bleeding disorders, that window carries real risk.

It is a design choice, not a biological necessity.

Patients should understand it before consenting to enroll.

HOW A NEW THERAPY ACTUALLY REACHES YOU

Months 0–2BLA submissionESTABLISHED

The sponsor files a Biologics License Application with the full trial dataset — the formal request for approval (e.g. the VGA039 pathway).

Months 2–10Regulatory reviewESTABLISHED

Regulators scrutinize efficacy, safety and manufacturing; advisory committees may weigh in. Priority review can compress this window.

Decision pointApprovalLIKELY

Approval defines the exact indication and label — which subtypes and populations can receive the therapy.

Months 0–6 (post-approval)Manufacturing scale-upESTABLISHED

Cell/gene and biologic therapies require complex, capacity-limited manufacturing — scale-up governs how quickly real patients can be treated.

Months 3–12Specialty pharmacy networkESTABLISHED

Distribution is built through specialty pharmacies and Hemophilia Treatment Centers qualified to deliver and monitor the therapy.

Months 6–18Insurance & pricingLIKELY

Payers negotiate coverage, and for multi-million-dollar one-time therapies, outcomes-based or installment models are worked out — often the true rate-limiting step.

Then — and ongoingFirst patients treatedLIKELY

The first commercial patients are dosed at qualified centers, and long-term registries begin tracking durability and safety in the real world.

THE FACTOR DISORDERS AT A GLANCE

CORE CLOTTING FACTORS

  • Factor VIII — Hemophilia A

    Amplification-phase cofactor; deficiency causes Hemophilia A. Addressed by emicizumab, factor replacement and Roctavian gene therapy.

  • Factor IX — Hemophilia B

    Propagation-phase factor; deficiency causes Hemophilia B. The Hemgenix functional cure restores endogenous Factor IX.

VON WILLEBRAND & FACTOR XI

  • Von Willebrand factor (VWF)

    Platelet-adhesion and Factor VIII-carrier protein; deficiency/dysfunction causes von Willebrand disease. Anti–Protein S therapy (VGA039) is the first targeted approach.

  • Factor XI

    Amplification-phase factor; deficiency (Hemophilia C) causes variable bleeding, and Factor XI inhibition is a major cross-purpose drug-development target.

STABILIZATION & REGULATORY FACTORS

  • Factor XIII

    Cross-links fibrin in the propagation phase; deficiency destabilizes the finished clot. Concentrate is approved; AAV gene therapy is in trials.

  • Protein C / Protein S

    Natural anticoagulants; the rebalancing strategy and VGA039 modulate this regulatory axis to restore net thrombin generation.

GETTING TRIAL- AND THERAPY-READY

A prioritized preparation sequence — built from the von Willebrand readiness pathway but applicable across bleeding disorders — so eligibility can be confirmed the moment a therapy or trial slot opens.

1
Confirm your exact diagnosis and subtypeCRITICAL

Obtain specific factor assays and, for VWD, a full panel (VWF:Ag, VWF activity, Factor VIII) plus genotype — therapy is subtype-specific.

2
Test AAV5 antibody status (if considering gene therapy)CRITICAL

Pre-existing anti-AAV5 antibodies are the single gatekeeper for gene-therapy eligibility — know this early.

3
Document a quantitative bleeding historyIMPORTANT

Record annualized bleed rate, treatment frequency, joint health and any inhibitor history — the baseline for every decision.

4
Establish care at a Hemophilia Treatment CenterIMPORTANT

HTCs deliver and monitor advanced therapies and independently improve outcomes — be connected before you need them.

5
Complete baseline safety labsRECOMMENDED

Liver assessment (for AAV therapies), inhibitor testing, and a Protein S level for VWD candidates — so nothing delays confirmation of eligibility.

6
Verify trial washout and crossover design before enrollingRECOMMENDED

Confirm whether a treatment-free window is required and whether external-control designs avoid it — a safety-critical question in severe phenotypes.

THIS MONTH

  • Confirm diagnosis and subtype
  • Request AAV5 antibody test if relevant

NEXT 3 MONTHS

  • Connect with a Hemophilia Treatment Center
  • Assemble bleeding-history and records binder

6–12 MONTHS

  • Complete baseline safety labs
  • Evaluate trials and their washout designs

WHEN A THERAPY IS APPROVED FOR YOU

  • Confirm eligibility quickly
  • Decide with your HTC, weighing durability and one-shot immunity

QUESTIONS FOR YOUR SPECIALIST

  • Given my subtype, which approved or trial therapies actually apply to me?
  • What is my AAV5 antibody status and does it open or close gene therapy?
  • How do the durability data look for the specific therapy you would recommend?
  • If I join a trial, is there a treatment-free washout — and is there a safer design?
  • What thrombotic monitoring would a rebalancing therapy require for me?
WHY THIS DOMAIN MATTERS

The First Functional Cures Are Already Here

Hematology is the proof-of-concept domain for the entire cure protocol: a single infusion now makes a person with Hemophilia B produce their own clotting factor for years. That is not management — it is a functional cure, delivered, approved and tracked in the real world. The playbook (validated target, durable delivery, hard endpoint) is now propagating to Hemophilia A, von Willebrand disease and beyond.

  • Hemophilia B: a durable functional cure, approved and delivered
  • Hemophilia A: gene therapy approved, durability the remaining work
  • Von Willebrand disease: first mechanism-specific therapy in pivotal trials
THE BOTTOM LINE

Where You Stand Depends on Your Exact Diagnosis

The honest framing: Hemophilia B has a functional cure now; Hemophilia A has one whose durability is still being defined; von Willebrand disease is on the cusp of its first targeted therapy; and the rare factors and platelet disorders remain uneven. Which reality applies to you depends entirely on your specific subtype, inhibitor status and AAV eligibility — which is exactly why precise diagnosis and early screening are the highest-leverage steps.

PLATFORMS SHARED WITH OTHER FIELDS

BORROWED FROM HEPATOLOGYLiver-directed AAV gene-delivery platform

Both Hemgenix and Roctavian deliver their transgene to hepatocytes — the same liver-directed AAV platform now advancing for inherited metabolic liver diseases. Advances in liver-targeted capsids, expression cassettes and immune management flow directly between the fields, improving durability and eligibility for both.

BORROWED FROM OPHTHALMOLOGYThe one-time AAV gene-therapy blueprint

The first approved AAV gene therapies validated the single-administration model — durable expression from one dose — that hemophilia gene therapy now realizes at scale, sharing lessons on capsid immunity and long-term durability tracking.

AI DRUG DISCOVERY: COMPRESSING THE TIMELINE

A stage-by-stage comparison of traditional drug-development timelines against AI-compressed ones for this domain, with the tooling, organizations, and breakthroughs driving the collapse.

AI TOOLS
AI Coagulation ModelingCRISPR Factor CorrectionAAV Vector OptimizationDigital Twin Dosing
KEY ORGANIZATIONS
BioMarinCSL BehringSpark TherapeuticsPfizeruniQure
BREAKTHROUGHS
  • Hemgenix (etranacogene dezaparvovec) — first gene therapy for hemophilia B, FDA-approved 2022
  • Roctavian (valoctocogene roxaparvovec) — gene therapy for hemophilia A, FDA-approved 2023
  • CRISPR-based in vivo factor VIII correction entering Phase I trials
  • AI-designed AAV capsids showing 100× improved liver tropism

CLINICAL TRIALS TO WATCH

A curated registry of the most relevant active and observational trials in this domain, with sponsor, focus, enrollment, and sites.

VIVID-6 — Subcutaneous VGA039 for Von Willebrand Disease (Phase 3)TRIAL

Vega Therapeutics (Star Therapeutics)

A Phase 3, open-label study of VGA039 — a first-in-class subcutaneous antibody that rebalances coagulation by targeting Protein S — given as prophylaxis to reduce bleeding across every type of von Willebrand Disease. A 24-week observational run-in is followed by ~49 weeks of treatment, sidestepping the need for frequent VWF-concentrate infusions.

~60 participants aged 12–75 with VWD (ABR ≥12/year)US — AR, CA, GA, MN + virtual (Science 37); multicenter
Early Genomic Testing for Inherited Bleeding DisordersTRIAL

Queen's University

Tests whether DNA testing (300+ genes linked to bleeding and clotting) introduced earlier in the diagnostic process can shorten the journey for the up to half of patients labeled "bleeding disorder of unknown cause."

Recruiting — standard vs. standard + early genomic testingCanada — Kingston & Ottawa, ON (Toronto site planned)
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders (MWELL)TRIAL

Oregon Health & Science University

Compares the levonorgestrel IUD (LNG-IUD) vs. oral norethindrone acetate (NETA) for heavy menstrual bleeding in adolescents and young adults with inherited bleeding disorders, tracking bleeding, quality of life, and iron restoration over six months.

~300 participants aged 10–24 (multicenter)US — OHSU Portland + CA, CO, GA, MI, MO, PA, WA (planned)

This decision-support view is generated from structured, source-grounded data for editorial and educational purposes. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician about your specific situation.

PERSONALISED TRIAL MATCHING

Describe your situation — we’ll match you to real recruiting trials

Tell us your condition, subtype, current treatment, and what you’re interested in. We’ll rank live ClinicalTrials.gov studies by relevance to your specific situation, and explain why each one might matter. Not medical advice — always consult your doctor.

0/1000 · The more specific you are, the better the matches.
EXAMPLE SITUATIONS
TRIAL ELIGIBILITY PRE-SCREENER

Could You Be a Candidate?

This is not medical advice. This is a structured way for you to think through whether a clinical trial conversation with your specialist is worth having — and to walk in prepared, not passive.

The Obligatory (But Genuine) Disclaimer

Talk to your doctor. Seriously. Yes, you probably know more about your specific condition than your GP does — you live in this body 24/7 and they see you for 15 minutes twice a year. But they went to medical school, they understand drug interactions, and they\'re the ones who can actually refer you to trials. This screener generates talking points, not prescriptions. Think of it as arming yourself for a productive conversation with the appropriate human in the loop.

14 questions · ~2 minutes

No data stored. No tracking. Just you and some clarity.

LIVE TRIAL FINDER

Real recruiting trials, pulled live from ClinicalTrials.gov

These are actual studies enrolling patients right now. Always talk to your own doctor before contacting any trial — this is a starting point, not medical advice.

No matching trials found. Try clearing the location filter or switching to “All active.”